ERC-StG ERC-PoC An applicant's perspective

GEORGIOS T. STATHOPOULOS MD PHD

LABORATORY FOR MOLECULAR RESPIRATORY CARCINOGENESIS, DEPARTMENT OF PHYSIOLOGY, FACULTY OF MEDICINE, UNIVERSITY OF PATRAS, GREECE, GSTATHOP@UPATRAS.GR,

HTTP://WWW.LMRC.UPATRAS.GR

COMPREHENSIVE PNEUMOLOGY CENTER @ INSTITUTE FOR LUNG BIOLOGY AND DISEASE, LUDWIG-MAXIMILIANS-UNIVERSITY AND HELMHOLTZ ZENTRUM MÜNCHEN. STATHOPOULOS@HELMHOLTZ-MUENCHEN.DE, HTTP://WWW.CPC-MUNICH.ORG









INTRO INTO RESEARCH FOCUS

HOW THE ERC CAME INTO MY LIFE

MY ERC STG STORY

MY ERC POC STORY

WHAT I WOULD DO THE SAME ALL OVER AGAIN

THINGS I WOULD DO DIFFERENTLY

Malignant Pleural Effusion (MPE) Adverse Event Vs Ca Hallmark

Aerobic glycolysis

inhibitors

EGFR inhibitors

VEGF signaling

Cyclin-dependent kinase inhibitors

> Inhibitors of HGF/c-Met


Immune activating anti-CTLA4 mAb


Selective anti-

Inhibitors

















A paradigm for tumor-host interactions?





Stathopoulos GT, Zhu Z, Everhart MB, Kalomenidis I, Lawson WE, Bilaceroglu S, Peterson TE, Mitchell D, Yull FE, Light RW, Blackwell TS. Nuclear factor-kappaB affects tumor progression in a mouse model of malignant pleural effusion. Am J Respir Cell Mol Biol. 2006 Feb;34(2):142-50.

Stathopoulos GT, Kollintza A, Moschos C, Psallidas I, Sherrill TP, Pitsinos EN, Vassiliou S, Karatza M, Papiris SA, Graf D, Orphanidou D, Light RW, Roussos C, Blackwell TS, Kalomenidis I. Tumor necrosis factor-alpha promotes malignant pleural effusion. Cancer Res. 2007 Oct 15;67(20):9825-34.

Stathopoulos GT, Sherrill TP, Cheng DS, Scoggins RM, Han W, Polosukhin VV, Connelly L, Yull FE, Fingleton B, Blackwell TS. Epithelial NF-kappaB activation promotes urethane-induced lung carcinogenesis. Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18514-9.

Stathopoulos GT, Sherrill TP, Han W, Sadikot RT, Polosukhin VV, Fingleton B, Yull FE, Blackwell TS. Use of bioluminescent imaging to investigate the role of nuclear factor-kappaBeta in experimental non-small cell lung cancer metastasis. Clin Exp Metastasis. 2008;25(1):43-51.


Stathopoulos GT, Sherrill TP, Han W, Sadikot RT, Yull FE, Blackwell TS, Fingleton B. Host nuclear factor-kappaB activation potentiates lung cancer metastasis. Mol Cancer Res. 2008 Mar;6(3):364-71.


Stathopoulos GT, Moschos C, Loutrari H, Kollintza A, Psallidas I, Karabela S, Magkouta S, Zhou Z, Papiris SA, Roussos C, Kalomenidis I. Zoledronic acid is effective against experimental malignant pleural effusion. Am J Respir Crit Care Med. 2008 Jul 1;178(1):50-9.


Stathopoulos GT, Psallidas I, Moustaki A, Moschos C, Kollintza A, Karabela S, Porfyridis I, Vassiliou S, Karatza M, Zhou Z, Joo M, Blackwell TS, Roussos C, Graf D, Kalomenidis I. A central role for tumor-derived monocyte chemoattractant protein-1 in malignant pleural effusion. J Natl Cancer Inst. 2008 Oct 15;100(20):1464-76.

Stathopoulos GT, Sherrill TP, Karabela SP, Goleniewska K, Kalomenidis I, Roussos C, Fingleton B, Yull FE, Peebles RS Jr, Blackwell TS. Host-derived interleukin-5 promotes adenocarcinoma-induced malignant pleural effusion. Am J Respir Crit Care Med. 2010 Nov 15;182(10):1273-81.

MPE A molecular culprit of KRAS-driven paracrine signaling?







Ji H et al. Oncogene 2006;25:2105–12 Sparmann A et al. Cancer Cell 2004;6:447-58

INTRO INTO RESEARCH FOCUS

HOW THE ERC CAME INTO MY LIFE

MY ERC STG STORY

MY ERC POC STORY

WHAT I WOULD DO THE SAME ALL OVER AGAIN

THINGS I WOULD DO DIFFERENTLY

Journal of Neuroscience Methods 221 (2014) 189-195



Contents lists available at ScienceDirect

Journal of Neuroscience Methods




journal homepage: www.elsevier.com/locate/jneumeth

Computational Neuroscience

Semi-automatic sleep EEG scoring based on the hypnospectrogram



Andreas M. Koupparis, Vasileios Kokkinos, George K. Kostopoulos*



Prof. GK Kostopoulos MD PhD Chair, Dpt. Of Physiology, Med, UoP



Prof. TS Blackwell MD Chair, Dpt. Of APCCM, Med, VUMC




Figure 1. Mutant KRas is linked with the ability of tumor cells to form a MPE. (A) MPE volume, (B) photograph's of MPEs taken via the diaphragm, and (C) survival of C57BL/6 mice with MPEs induced by various syngeneic tumor cells. Lung (LLC) and colon (MC38) adenocarcinomas cause MPE formation, in contrast to AE17 pleural mesothelioma and B16 skin melanoma cells. MPEcompetent tumor cells display KRas mutations and constitutive Ras signalling (D), which is linked with constitutive alternative, but not canonical NF-κB activation (E). *** P < .001 compared with other cell






Figure 2. KRas promotes alternative NF-kB activation and MPE formation in mice. (A) Compared with a control plasmid (pCMV), forced transduction of a wt KRas- and GFP-encoding bicistronic plasmid (pCMV.KRas.GFP) in B16 skin melanoma cells causes enhanced Ras activation in unstimulated conditions, increased alternative NF-kB activation, and renders these MPE-defective cells capable of MPE formation. (B) Compared with a control plasmid encoding random shRNA (pU6), forced transduction of a bicistronic plasmid encoding specific shRNA targeting KRas mRNA at position 727 and RFP (pU6.Ksh727.RFP) in MC38 cells limits Ras pathway activation in unstimulated conditions, inhibits constitutive alternative NF-kB activation, and renders these MPE-competent tumor cells incapable of MPE formation. *, *** P <.05 and P <.001 compared with other cell lines.

INTRO INTO RESEARCH FOCUS

HOW THE ERC CAME INTO MY LIFE

MY ERC STG STORY


MY ERC POC STORY

WHAT I WOULD DO THE SAME ALL OVER AGAIN

THINGS I WOULD DO DIFFERENTLY

http://www.ekt.gr/ NCP (CP)

https://erc.europa.eu/ Guide for applicants Guide for reviewers



Status At ERC Application

EXPATRIATE (US), DEPENDENT RESEARCH

NO NATURE, SCIENCE, CELL PAPER, BUT SEVERAL 1ST AUTHOR MID-RANGE (IF 5-15) PUBLICATIONS INCLUDING JNCI, PNAS, AJRCCM, CANCER RES, ETC.

GENERATED NEW/EXPANDED EXISTING FIELD

CLINICAL RELEVANCE

ERS MAURIZIO VIGNOLA AWARD

UPCOMING REPATRIATION ASST. PROF. POSITION (NOT DEPENDENT ON ERC FUNDING, NO INSTITUTIONAL START-UP)

NO OTHER WAY TO GO

ERC Information Day, EKT, Athens 14.01.2016

What happened...

JUL 2009: HEARD OF ERC

NOV 2009: APPLIED FOR StG

FEB 2010: 1ST ROUND

MAY 2010: INTERVIEW

OCT 2010: FINAL RESULTS

DEC 2010: GA

FEB 2011: PREFINANCING

APR 2011: START DATE

OCT 2011: EXPERIMENTS



Applying for and (even more so) getting an ERC StG is like entering an arena with lions

Pressure to get things going

Pressure to publish high impact and to garner major accomplishments

Pressure to consolidate the group

Pressure for continued funding

Pressure escalates as approaching the CoG schemes

OPEN & ACCESS Freely available online

PLOS ONE

Beneficial Impact of CCL2 and CCL12 Neutralization on **Experimental Malignant Pleural Effusion**

Dimitrios Kardamakis⁴, C 1 Laboratory for Molecular Respire University of Patras, Rio, Achaia, Greeco

Abstract

Using genetic intervention pleural effusion (MPE) form potential of antibody-med i 6 mice by intrapleural or adenocarcinoma cells (AS adenocarcinoma cells (AS antibodies neutralizing mo three days. We found that formation by LLC cells. O Combined CCL2 and CCL12 in both syngeneic model derived CCL2 also contrib inhibition of immune and induced by murine and hi promise for future use aga

Citation: Marazioti A, Kairi CA, Spella Pleutal Effusion, PLoS ONE 808: e712 Received And 17 2013: Accepte Copyright: © 2013 Marazioti et al. unrestricted use, distribution, and re unding: This work was supported it tarting-grants) under the European

Competing Interests: Linda A. Si declare no conflict of interest. The E-mail: gstathop@upatras.gr

Malignant pleural effusion (N ffects patient survival and qu therapies targeting MPE patl However, MPE appears to be p to-host signaling events, in addit normal pleural fluid out fow [6]. culminate in MPE are progressit targeted pharmacotherapies agai

PLOS ONE | www.plosone.org

The Lymphatic System in Malignant Pleural Effusion Drain or Immune Switch?

Malignant pleural effusion (MPE) is a signi mesothelioma (1). Treatment is palliative removal or pleural space obliteration (2), with the traditional view of MPE pathog fluid accumulation in patients with cano the pleural surfaces with tumorigenic ob-evacuation tracts (3). In recent years, im-models of adenocarcinoma-induced MPE in American Thoracic Society journals (that an inflammatory signaling network l vascular and immune systems contribu Therapeutic targeting of this crosstalk u (6, 7). Until recently, the focus of trans restricted to deciphering the crosstalk b

yeloid immune cells, such as macropi In this issue of the Journal (pp. 6 report the contrasting functions of two subsets, Th1 and Th17, in two differer Th1 and Th17 cells in MPE, the investi lacking IFN-γ and IL-17A to show de cells on IFN-y and IL-17A, respectivel IFN-γ-dependent Th1 and IL-17A-de differentiation, and found them to inc transcription factors signal transducer a: 3 (STAT3)/T-bet and STAT1/RAR-relat (Figure 1), Most importantly, the author two lymphocyte subsets impact MPE de mice, devoid of Th1 and rich in Th17 cel whereas IL-17 A-deficient mice, rich in T had enhanced pleural fluid accumulation

The study by Lin and coworker observations of this group regarding h mouse MPE (10-12) by showing for t subsets are involved in sculpting the ple regulates intrapleural tumor disseminat (13), and eosinophils (5), previously si pathobiology, these studies darify a role progression. Despite these important fi which T cells affect pleural fluid home influence tumor cells and the pleural vas tumorigenic and vasoactive mediators, fine-tune other (myeloid) effector cells? and IFN-y have traditionally been repo immunity (14), which contrasts with the

PLOS ONE

OPEN ACCESS

pone.0132527

Received: March 3, 2015

Accepted: June 15, 2015

Published: July 6, 2015

Citation: Giopanou I. Lifs I. Papaleonidopoul Clattino: Gropanou I, Litis I, Paparennidopousis V, Mamzioti A, Spella M, Vreka M, et al. (2015) Comprehensive Evaluation of Nuclear Factor-kB Expression Patterns in Non-Small Cell Lung Canor PLoS ONE 10(7): e0132527. doi:10.1371/journal.

Convright @ 2015 Giogenou et al. This is an oper

medium, provided the original author and source a

PLOS ONE LDOI:10.1371/journal.none.0

Published OnlineFirst February 17, 2015; DOI: 10.1158/0008-5472.CAN-14-2376

The Journal of Clinical Investigation

Theodora Agalloti,1 and Georgios T. Stathopoulos 14,11,10

formation

Mast cells mediate malignant pleural effusion

Anastasios D. Giannou,' Antonia Marazioti,' Maeda Spella,' Nikolaos I, Kanellakis,² Hara Apostolopoulou,' Ioannis Psaliidas,

Alexandra L. Patmanidi,² Ioanna Giopanou,¹ Nikolitsa Spiropoulou,¹ Vaggelis Harokopos,³ Vassilis Aidinis,¢ Dionisios Spyrato Stamptia Telinusi 8 Helen Panadaki 9 Stavros Taraviras 2 Linda A Spyder 10 Oliver Firkelherg 11 Dimitrios Kardamakis 10

*Laboratory for Molecular Respiratory Carcinogenesis, Department of Physiology, and "Stem Cell Biology Laboratory, Department of Physiology, Faculty of Medicine, University of Patras, File, Achaia, Greec Octord Centre for Respiratory Medicine, Churchill Hospital, Oxford, United Kingdom. "First Department of Critical Care and Pulmonary Medicine, University of Athens School of Medicine, General Hospital

Evangelismos, Athens, Attica, Greece. "Expression Profiling Unit and "Division of Immunology, Biomedical Sciences Research Center (BSRC) Alexander Fleming, Vari, Attica, Greece. "Department of

Stereotactic Radiotherapy, Faculty of Medicine, University of Patras, Rio, Achaia, Greece. "Research Institute for Biomedical Sciences, Tolyo University of Science, Tolyo, Japan. "Univision for Cellul

centrum (DKFZ). Heidelberr, Baden-Württemberr, Germany, "Department of Medicine, Dicision of Alleroy, Pulmonary and Critical Care Medicine, Vanderbil

Austramy Faculty of Medicine University of Patrax, Rin Arbaia, Goeco "Oncolony Discovery Research, Lancese RACOLLE, Sorine House Pennsylvania, USA, "Comprehensive Preumainey Center (CPC) University Hospital, Ludwig-Maximilians University and Heimholtz Zentrum München, Member of the German Center for Lung Research (1921), Munich, German, "Department of Radiation Uncology and

Zeliko M. Prijovich., Majamati Vreka, Dimitra E. Zazara, Joannis Lilis, Vassilios Papaleonidopoulos, Chrysoula A. Kairi, 4

Yolchiro lwakura,13 Thorsten B. Feyerabend,14 Hans-Reimer Rodewald,14 loannis Kalomenidis,14 Timothy S. Blackwell,

Epilogue

RESEARCH ARTICLE

Interleukin-5 F Modulating the

Rinat Zaynagetdinov¹, T Jamie A. Saxon², Arun R. Stokes Peebles, Jr.^{1,5}, Timothy S. Blackwell^{1,2,1}

Abstract

Although the lung is the cancer cells, biologic mechani not fully understood. Using I tion models of lung metasta cytokine involved in allergic metastatic colonization through metastatic colonization thro phils and regulation of other microenvironment of the d offered marked protection of ent types of tumor cells, incl colon cancer. IL5 neutralizat

Most cancer deaths occomplications, and the lun complications, and the lungs a for a variety of cancers (1). process, which includes detac primary tumor, intravasation the bloodstream, extravasatio of extracellular matrix, and Although the majority of mali and colonization stages due t develop the ability to escap

Funding: This work was supported by a European o role in study design, data collection and analysis

Corresponding Author: Rinat Zayna; Medicine, 1161 21st Avenue South, T-12 615-34 3-17 73; Fax: 615-322-2582; E-m

Mast cells (MCs) have been identified in various tumors; however, the role of these cells in tumorigenesis remains. controversial. Here, we quantified MCs in human and murine malignant pleural effusions (MPEs) and evaluated the fat and function of these cells in MPE development. Evaluation of murine MPE-competent lung and colon adenocarcinoma osteopontin. MCs were required for effusion development, as MPEs did not form in mice lacking MCs, and pleural infusion of MCs with MPE-incompetent cells promoted MPE formation. Once homed to the pleural space, MCs released tryptase A and II.18 which in turn induced pleural vasculature leakiness and triggered NE.x8 activation in pleural tumor cells, therein ostering pleural fluid accumulation and tumor growth. Evaluation of human effusions revealed that MCs are elevated in MPES compared with bonion effusions. Moreover, MC abundance correlated with MPE formation in a human cancer cell. induced effusion model. Treatment of mice with the c-KIT inhibitor imatinib mesylate limited effusion precipitation by mous and human adenocarcinoma cells. Together, the results of this study indicate that MCs are required for MPE formation and suggest that MC-dependent effusion formation is therapeutically addressable

Inflammation was recently recognized as an enabling hallmark of cancer that may mediate tumor growth and dissemination instead of tumor eradication (1). Inflammatory signaling networks in the tumor microenvironment can be initiated and orchestrated by malignant or immune cells; the networks conditionally facilitate tumor progression or regression depending on tumor type, immune effector cell type, and anatomic context (2-4). The identification of such inflammatory loops is of particular interest in the hunt for anticancer therapies that are anticipated to be more effective and less toxic than conventional chemotherapy (5).

Authorship note: Timothy S. Blackwell, Theodora Agalloti, and Georgios T. Stathopoulos

Submitted: November 14, 2014; Accepted: March 26, 2015.

mast cells (MCs) were recently found to be recruited to they are relatively sparse, MCs are appealing candidates fo tumor promotion, since they can release a battery of mediator to orchestrate the tumor milieu (8-11). However, MCs were foun to be tumor-protective or indifferent in other settings (12-14) not known, new models of MC deficiency lend promise to solve

this riddle (15, 16). Malignant pleural effusion (MPE) is extremely common in patients with lung, breast, or other adenocarcinomas (17, 18). No treatment exists, and palliative attempts may cause further morbidity and mortality (19, 20), MPE was recently reclassified as a parate stage of lung cancer, since it was acknowledged to rep esent a distinct form of metastatic disease with very short surviva (18, 21, 22). Simultaneously, we and others used mouse models

Who u r competing against... ERC-CoG results 2014

Last Name First Name		Host Institution English Name
ADAMEYKO	lgor	Medical University of Vienna
BOLLBACK	Jonathan Paul	Institute of Science and Technology Austria
MARTENS	Sascha	University of Vienna
STARK	Alexander	The Research Institute of Molecular Pathology
AMANT	Frederic	Catholic University of Leuven
BRAECKMANS	Kevin	Ghent University
LANCELLOTTI	Patrizio	University of Liege
REMAUT	Han	Flanders Institute for Biotechnology (VIB)
SANTORO	Massimo	Flanders Institute for Biotechnology (VIB)
SCHYMKOWITZ	Joost	Flanders Institute for Biotechnology (VIB)
VERSTREKEN	Patrik	Flanders Institute for Biotechnology (VIB)
STEFL	Richard	Masaryk University
SVOBODA	Petr	Institute of molecular genetics of the Czech Academy of Science
BRAUN	Pascal	Technical University of Munich
BRIGGS	John	European Molecular

2015 European Research council - http://erc.europea.eu

Last Name	First Name	Host Institution English Name	
SCHNABEL	Renate	University Hospital Hamburg	
SELENKO	Philipp	Forschungsverbund Berlin e.V.	
SIMONS	Mikael	Max Planck Society	
STAFFORST	Thorsten	University of Tübingen	
TEICHMANN	Sarah	European Molecular Biology Laboratory	
THUM Thomas		Hannover Medical School	
VON KRIEGSTEIN	Katharina	Humboldt University of Berlin	
WERNER	Christiane	University of Bayreuth	
WIEDEMANN	Nils	University Medical Center Freiburg	
ZENDER	Lars	University of Tübingen	
CHOUDHARY	Chunaram	University of Copenhagen	
KJELDSEN Frank		University of Southern Denmark	
LOOG	Mart	University of Tartu	
GARINIS	Georgios	Greek Foundation for Research and Technology	

2015 European Research council - http://erc.europea.eu

Last Name	First Name	Host Institution English Name
MASTER	Emma	Aalto University
MUSTJOKI	Satu	University of Helsinki
AGUILANIU	Hugo	National Center for Scientific Research (CNRS)
ALIZON	Samuel	National Center for Scientific Research (CNRS)
BAJÉNOFF	Marc	National Center for Scientific Research (CNRS)
CASTRIC	Vincent	National Center for Scientific Research (CNRS)
COSSART	Rosa	National Institute of Health and Medical Research (INSERM)
GRANIER	Sebastien	National Institute of Health and Medical Research (INSERM)
GUTSCHE	Irina	National Center for Scientific Research (CNRS
JARRIAULT	Sophie	CERBM
LEGUBE	Gaelle	National Center for Scientific Research (CNRS)
LIVET	Jean	University Pierre et Marie Curie
PEDUTO	Lucie	Pasteur Institute

2015 European Research council - http://erc.europea.es

Last Name	First Name	Host Institution English Name
MILO	Ron	Weizmann Institute of Science
PEER	Dan	Tel Aviv University
SCHULDINER	Maya	Weizmann Institute of Science
SHOHAM	Shy	Technion - Israel Institute of Technology
DEMICHELIS	Francesca	University of Trent
GENOVESIO	Aldo	Sapienza University of Rome
ROMAGNANI	Paola	University of Florence
BAETEN	Dominique	Academic Medical Centre, University of Amsterdam
DARAN- LAPUJADE	Pascale	Delft University of Technology
DE JONG	Hugo	University Medical Center Utrecht
HOLLMANN	Frank	Defft University of Technology
JADDOE	Vincent	Erasmus Medical Center Rotterdam
KLAVER	Caroline	Erasmus Medical Center Rotterdam
MALDA	Jos	University Medical Center Utrecht

2015 European Research council - http://erc.europea.eu

itor Grants 2014 results	List of principal investigators -	- Life s

institution at time of application

Last Name	First Name	Host Institution English Name	Host Institution Local Name	Host Country	Acronym	Project Title	Pane
CARROLL	Jason	University of Cambridge	University of Cambridge	UK	ER_disease	Defining hormonal cross-talk and the role of mutations in estrogen receptor positive breast cancer	LS4
CHARRAS	Guillaume	University College London	University College London	UK	MolCellTissMech	Molecular and cellular determinants of cell monolayer mechanics	LS3
DUPUY	Lionel	The James Hutton Institute	The James Hutton Institute	UK	SENSOILS	Sensing soil processes for improved crop nitrogen bioavailability	LS9
FIRTH	Andrew	University of Cambridge	University of Cambridge	UK	ERVE	Systematic discovery of functional elements in RNA virus genomes: an Encyclopedia of RNA Virus Elements	LS6
GADEGAARD	Nikolaj	University of Glasgow	University of Glasgow	UK	FAKIR	Focal Adhesion Kinetics In nanosurface Recognition	LS9
GRIFFIN	Ashleigh	University of Oxford	University of Oxford	UK	SESE	Social Evolution and Social Engineering of bacterial Infections	LS8
GUDELJ	Ivana	University of Exeter	University of Exeter	UK	MathModExp	The Evolution of Competition and Cooperation: how polymorphisms in microbial populations optimise virulence and mediate drug resistance	LS8
HAJKOVA	Petra	Imperial College of Science, Technology and Medicine	Imperial College of Science, Technology and Medicine	UK	dynamicmodifications	Complexity and dynamics of nucleic acids modifications in vivo	LS2
HUANG	Danny	Beatson Institute For Cancer Research LBG	Beatson Institute For Cancer Research LBG	UK	RINGE3	Structural and mechanistic insights into RING E3-mediated ubiquitination	LS1
HUISKONEN	Juha	University of Oxford	University of Oxford	UK	BIZEB	Bio-Imaging of Zoonotic and Emerging Bunyaviruses	LS1
HUNTLY	Brian	University of Cambridge	University of Cambridge	UK	COMAL	COMAL COhesin Mutations in Acute Leukemia: from modeling and mechanisms to novel therapeutics	LS7
IANNETTI	Giandomenico	University College London	University College London	UK	PAINSTRAT	Novel neurophysiological techniques to quantify pain and stratify patients	LS7
ISAACS	Adrian	University College London	University College London	UK	C9ND	C9orf72-mediated neurodegeneration: mechanisms and therapeutics	LS5
JEFFERIS	Gregory	Medical Research Council	Medical Research Council	UK	OffSwitch	OffSwitch: Neural circuit switches from molecules to behaviour	LS5
KASER	Arthur	University of Cambridge	University of Cambridge	UK	IMMUNOBIOME	Identifying microbiotal triggers of inflammatory bowel disease through the lens of the immune system	LS7
KAYSER	Christoph	University of Glasgow	University of Glasgow	UK	DynaSens	Understanding the neural mechanisms of multisensory perception based on computational principles	LS5

Page 9 of 10

FRC Consolidator Grants 2014 results

Last Name	First Name	Host Institution English Name
DE MEAUX	Juliette	University of Munster
FEUERER	Markus	German Cancer Research Centre
FILLATREAU	Simon	German Rheumatism Research Centre Berlin
FISCHER	André	German Centre for Neurodegenerative diseases
GREB	Thomas	University of Heidelberg
GROSS-HARDT	Rita	University of Bremen
HÖCKER	Birte	Max Planck Society
HORNUNG	Veit	University Medical Centre Bonn
HUISKEN	Jan	Max Planck Society
KORN	Thomas	University Hospital Rechts der Isar
LIU	Haikun	German Cancer Research Centre
PILLAI	Ramesh	European Molecular Biology Laboratory
PLESTED	Andrew	Forschungsverbund Berlin e.V.
RINK	Jochen	Max Planck Society
SAUR	Dieter	University Hospital Rechts der Isar

2015 European Research council - http://erc.europea.eu

FRC Consolidator Grants 2014 results

Last Name	First Name	Host Institution English Name	
CORTÉS LEDESMA	Felipe	Spanish National Research Council (CSIC)	
GIRALDEZ	Teresa	University of La Laguna	
GONZALEZ	Susana	Spanish National Centre for Cardiovascular Research	
GONZÁLEZ BRAVO	Ignacio	Catalan institute of Oncology	
GONZALEZ PEREZ	Josefa	Spanish National Research Council (CSIC)	
LOPEZ BENDITO	Guillermina	Spanish National Research Council (CSIC)	
LOPEZ CORTAJARENA	Aitziber	IMDEA Nanoscience	
MAESTRE GIL	Fernando Tomás	King Juan Carlos University of Madrid	
MENDEZ- FERRER	Simon	Spanish National Centre for Cardiovascular Research	
MENENDEZ	Pablo	Josep Carreras Leukaemia Foundation	
TOLEDO	Alejandro	Spanish National Research Council (CSIC)	

2015 European Research council - http://erc.europea.eu

FRC Consolidator Grants 2014 results

Last Name	First Name	Host Institution English Name
PERROY	Julie	National Center for Scientific Research (CNRS)
PFEFFER	Sebastien	National Center for Scientific Research (CNRS)
RADMAN-LIVAJA	Marta	National Center for Scientific Research (CNRS)
RODRIGUEZ	Raphael	Curie Institute
RONDELEZ	Yannick	National Center for Scientific Research (CNRS)
SPASSKY	Nathalie	National Institute of Health and Medical Research (INSERM)
SUZANNE	Magali	National Center for Scientific Research (CNRS)
UGOLINI	Sophie	National Institute of Health and Medical Research (INSERM)
TOLIC	Iva	Ruder Boskovic Institute
PAL	Csaba	Biological Research Centre, Hungarian Academy of Sciences
BRENNAN	Lorraine	University College Dublin
GOLDBERG	Joshua	The Hebrew University of Jerusalem
KADENER	Sebastian	The Hebrew University of Jerusalem
LINDELL	Debbie	Technion - Israel Institute of Technology

2015 European Research council - http://erc.europea.eu

FRC Consolidator Grants 2014 results

Last Name	First Name	Host Institution English Name
VAN RHEENEN	Jacco	Royal Netherlands Academy of Arts and Sciences
HEJNOL	Andreas	Uni Research AS
LOUCH	William	University of Oslo
BARATA	João	Institute of Molecular Medicine, Lisbon
MOITA	Luis	Calouste Gulbenkian Foundation
SILVA PEREIRA	Cristina	ITQB - New University of Lisbon
SILVA-SANTOS	Bruno	Institute of Molecular Medicine, Lisbon
VEIGA FERNANDES	Jose Henrique	Institute of Molecular Medicine, Lisbon
JOHANNESSON	Hanna	Uppsala University
LARSSON	Jonas	Lund University
MAKINEN	Taija	Uppsala University
ORHO- MELANDER	Marju	Lund University
SANDBERG	Rickard	Karolinska Institute
SVENNINGSSON	Per	Karolinska Institute
ALBERT	Joerg	University College London
BASS	Chris	Rothamsted Research Limited

2015 European Research council - http://erc.europea.eu

FRC Consolidator Grants 2014 results

2015 European Research council - http://erc.europea.eu

		List of	principal	investigators	-Life	science
--	--	---------	-----------	---------------	-------	---------

10/03/2015

Host institution refers to

Last Name	First Name	Host Institution English Name	Host Institution Local Name	Host Country	Acronym	Project Title	Panel
LUMMAA	Virpi	University of Sheffield	University of Sheffield	UK	Elephant Project	How elephants grow old	LS8
MALLUCCI	Giovanna	Medical Research Council	Medical Research Council	UK	UPR NEURO	The Unfolded Protein Response in Neurodegeneration	LS5
MANICA	Andrea	University of Cambridge	University of Cambridge	UK	LocalAdaptation	Detecting Local Adaptation with Climate- Informed Spatial Genetic Models	LS8
MERCER	Jason	University College London	University College London	UK	UbiProPox	Modulation of the Ubiquitin Proteasome System During Multiple Stages of the Poxvirus Lifecycle	LS6
MORGAN	Craig	King's College London	King's College London	UK	REACH	REACH: Risk, Resilience, Ethnicity and AdolesCent Mental Health	LS7
PAPAVASILIOU	Nina	University of Cambridge	University of Cambridge	UK	RNAEDIT	RNA EDITING IN HEALTH AND DISEASE	LS6
PATTON	Elizabeth	University of Edinburgh	University of Edinburgh	UK	ZF-MEL-CHEMBIO	Chemical Biology in Zebrafish: Drug-Leads and New Targets in the Melanocyte Lineage and Melanoma	LS4
SIEBOLD	Christian	University of Oxford	University of Oxford	UK	CiDyn	Molecular analysis of the Hedgehog signal transduction complex in the primary clium	LS1
TOLAR	Pavel	Imperial College of Science, Technology and Medicine	Imperial College of Science, Technology and Medicine	UK	BCELLMECHANICS	Regulation of antibody responses by B cell mechanical activity	LS6
TURNER	James	Medical Research Council	Medical Research Council	UK	XChromosome	Functions of the X chromosome in the mammalian germ line	LS3
WILSON	Mark	Medical Research Council	Medical Research Council	UK	miRNA in Immunity	Testing the role of miRNA-mediated non-cell autonomous gene regulation in type-2 immunity	LS6

10/03/2015

Page 10 of 10

INTRO INTO RESEARCH FOCUS

HOW THE ERC CAME INTO MY LIFE

MY ERC STG STORY

MY ERC POC STORY

WHAT I WOULD DO THE SAME ALL OVER AGAIN

THINGS I WOULD DO DIFFERENTLY

Why the heck would you apply??? (for a PoC if you have a StG or CoG or AdG)

Top-up money (so not true, need to design and steer separate project)

Commercialize an idea (so not true, just seed money)

Fund an idea to make it happen (the truth: to start making it happen)

Because it's a piece of cake compared to the big ERC grants (so not true, technical writing as compared with scientific writing, assessment criteria)

Because it requires less writing (so not true, 10 pages fro 150 K as compared with 20 pages for several M)

Because it has double or triple the success rate as the big ones (so not true, the denominator is ERC grantees)

The speaker got his StG at once, his PoC after 3 failures

Why the heck would you not apply??? (for a PoC)

Ha, ha, because I already got one (so not true, can apply for up to two projects as long as they do not overlap in time)

Cause by ERC ran out last year (so not true, can apply up to two years post-ERC)

Cause I do not like doing business, I am a basic scientist (the truth, it is a world-wide trend: science-application-money)

Because I already have enough money with my ERC grant (so not true, there is no better time to apply for additional grants than when you're ERC-funded)

Because I only like working alone (so true, best partner up with liaison before applying)

Because I do not understand the managerial jargon in the call (so true, you need a liaison to write it)

ERC Information Day, EKT, Athens 14.01.2016

What happened...

2013-14: 3 REJECTS FOR A COMPLEX IDEA (1 WITH LIAISON)

DEC 2014: IDENTIFIED NEW LIAISON

FEB 2015: APPLIED FOR NEW PROJECT (IDIOT PROOF)

MAY 2015: GOT IT (150 K)

NOV 2015:PREFINANCING

NOV 2015:START

DEC 2015: NEGOTIATE WITH LIAISON

JAN 2016: FULL DEPLOYMENT

cept Grant 2016 - Round I Lin

List of selected Principal Investigators (by country of host institution)

Last Name	First Name	Host Institution (English)	Host institution (local name)	Host Country	Acronym	Title
Severaler	àn.	VR - Fenders Institute for Motechnology	VR - Vaams Inditud voor Richardnoongie	86	AcTathetons	AcTributure: Tumor Necrosis Fector-based immuno cytokines with superior therapedic indexes
Lecog	Paul	European Organization for Nuclear Research (CERN)	Organisation Suropéenne pour la Recherche Nucléaire	ОН	ULTIMA.	LL Torbet Imaging sensor for Medical Applications
Quarteroni	Atto	Ecole Polytechnique Filidinale de Lausanne (EPFL)	Foole Polytechnique Fédérale de Lausenne	ОН	menerowski	A mathematical plactum for Accoming Acris Avectors (its excessment and surgical planning
State	Share	ETZ Unkenty Zolch	Ekigendesische Technische Hochschule Zotich	ю	BollaPo	A. Hit Spot Rb-Barcode Strategy for Prognostic Biomarkers in Coloractal Cancer
Section	Year	Store Storenberg	Spectrossing	OH.	Time2.fe	Advanced stored processing of time-domain data in mass specificmetry to inversor the sciences.
Som.	Christian	Karbother Ingitize of Technology	Kerkscher hecht faer Technologie	DE	HYPHEN	H/PHRY Hotel Plates Frains for Massie Cool Cornellidy
Service .	às.	Karbonier Inglishe of Technology	Kerksolver Institut Com Technologie	DE	LMGK	Mack ande collectring NMR on Belic scores - LMoX
Lennes	Teen	University Hospital Anches (UKA)	Unite streets/Silver Apolen	DE	CONQUEST	Companion Nanodiagnostics for Quantifying EPR and Stratifying Patients to Yargeted Nanodiananies
Leskin	Panel	Karbonier Inglishe of Technology	Kerksolver Institut Care Technologie	DE	CeltionerCitio	Nin-Ore Call Screening Chit: Device for Affordable High-Throughout Call Screenings
Nesterov-Moeler	Neander	Karlander Institute of Technology	Kerksher Institut foer Technologie	DE	PRESCREENWRRAY	Peptitie arrays as a high throughput pre-screening tool
Schener	Geos	audERRNO US (radigest Audo Engleweing)	audiERNO US (laturgosestatric)	DE	Voolimatek	Volue Emotion detection by Approximal Inference
Stairbach	Ediahard	Technische Unterstaat Manchen (TUM)	Technische Universität Moenchen	DE	RoW	Robotic manipulator with visuo-haptic sensing
Tomancak	Panel	Max Panck Society	Max Planck Gesellschaft zur Frenderung der Wissenschaften E.V.	DE	spinition	spirof Your customized existions for light sheet microscopes and imaging data energies.
Matter	Repor	University of Copenhagen	Koberheine Universität	DK	SUNJOHTNO	Herealing the Itus
Saffopodes	Osorgios	Linkently of Patres	University of Patrice	6.	SLACC	Supplying lung adenocarolnona cell lines to the cancer research community.
Calleja	Minheral	Spanish National Reseach Council (CSIC)	Agencia Ristati Consejo Superior De Investigaciones Clerificas	68	FAST SPECTRO	Spatish Multiplesed Spectrophosometry
Listera	Andrea	Spanish National Research Council (CSIC)	Agencia Estatal Consejo Superior De Investigaciones Cierdificas	68	WASP	Wide Spectral Range Photoric Obscorneter
Loose	No	legistra of Chamical Research of Catalonia (ECC)	Fundado Phind India Ottola (Prinagliado Quinta	FR	Robinical	His Date for Catalysis
Nebreda	Accel	Institute for Research in Ricmedicine (RR Recognition)	Fundacio Inditat de Recenza Ricmedica (IRR Receiona)	68	silicon	New treest cancer Sectories based on predicte citif MAPK inhibitors
Dates	Romain	CFO - The Indiana of Photoric Sciences	Fundado Indital de Ciences Estantases	FR	SMARTLENS	Reconfigurable smart lang for adaptive imaging
Serre	Kerler	Untenty Porces Fabre	Uniteralided Formoso Fabre	68	CAMUT	Culture America Munici Technologies
Amount	Connectors	trebit Curie	Instal Curie	FR	EPCO/OR	Foliands Politics of Cherodienov Fillians
Feder	Alein	National Institute of Health and Medical Research (Inserts)	Institut National de la Santé et de la Resilientée Médicale (MSERM)	FR	MFEMMUNOSUPPRESS	Development of immunosuppressive treatments with better safety
Gesti	Christian	Commissent à Sinergie atomique et aux linergies attenutives (CSA)	Commissariat à l'Émergie atomique et aux Émergies alternatives	FR	Ciertorios	Clearinal Levitories: transposing quantum levitors to cleasinal nerves for single-side band virtues data transmissions.
Luta	Jean-François	National Center for Scientific Research (CARS)	Centre National de la Restrente dicentifique	FR	Sequence Rarcodes	Product identification using sequence controlled alignment
Sourcella	Vessil	Institut Curie	Instal Curie	FR	Crughywrgy	Drugslynergy: A data-driven systems blobgy approach to optimize drug combination strategies
Mediorer	Sino.	The Hebreur University of Jensestern	The Hebres University of Jerusalem	L	Hattichend	An Antibody Microarray for Histone Modifications
Oree	Cen	Webmann Inditate of Science	Webmann Institute of Science		COLUM	Countum-dot doped polymer fibers for cheep and bright light sources.
Semonis	Yantena	Webmann Inditate of Science	Webmann Inditate of Science	L	COMAT	Commercialization of a novel tool for designing personalized nOvel Methodna Therapies
Yanai	tai	Technion leaved treditate of Technology	Section is ned institute of Technology		ARRAY SEQ	Array based since set one expression by parallel their RNA amplification and sequenting
led.	Roberto	University of Rome For Versita	Università deal Studi di Roma Tor Versata	п	FAST-ORVIS-OPS	Developing new Democratics for Friedmich storie
		The state of the s				




Figure 1 | Method of generation of mouse lung adenocarcinomas. Mice from the FVB and Balb/c backgrounds were injected weekly with to bacco carcinogens (grey arrows) urethane (1 g/Kg) or diethylnitrosamine (DEN; 200 mg/Kg) starting at six weeks after birth (pink arrows) and were observed for prolonged periods of time (each box represents one month). Lung tumors were dissected under sterile conditions, minced, and cultured for 80-100 passages (one year) using DMEM supplemented with 10% FBS, 2 mM L-glutamine, 1 mM pyruvate, 100 U/ml penicillin, and 100 mg/ml streptomycin. Cell line designator acronyms stand for originating Strain (first letter; F for FVB and B for Balb/c); causative Carcinogen (second letter; U for ureth ane and E for DEN); Lung Adenocarcinoma; Serial number in order of establishment.




Figure 2 | Validation of

adenocarcinomas. (A) In vitro proliferation rate of MLC compared with LLC cells.ns. not significant for comparison between MLC; *** P<0.001 for comparison of MLC with LLC cells by two-way ANOVA with Bonferroni post-tests. (B) In vitro cultured LLC and FULA1 cells with flat cuboidal cells (white arrows), spindle-shaped cells (filled black arrows), anchorage-independent cells (open black arrows), and primary tumorspheres (right). (C) Primary tumorspheres formed by all cell lines. * and **, P<0.05 and P<0.01 for comparison with LLC cells by one-way ANOVA with Bonferroni post-tests. (D) Subcutaneous tumorgrowth rates (top) and spontaneous lung metastases induced by subcutaneous delivery of a million LLC or MLC cells. Top ns, not significant for comparison between MLC: *** P<0.001 for comparison of MLC compared with LLC cells by two-way ANOVA with Bonferroni post-tests. Bottom: ns. *. **. and ***. P>0.05. P<0.05, P<0.01, and P<0.001 for comparisons indicated by one-way ANOVA with Bonferroni post-tests.

What is it about (idea 2p)

Syngeneic lung tumor models: LLC

Naturally induced lung tumors

Cell lines

Floxed cell lines

Tools for the CR community




Figure 3 | Kras mutations and Trp53 loss of mouse lung adenocarcinomas. (A) Representative Sanger sequencing traces of mouse lung adenocarcinomas showing heterozygous Kras codon 61 mutations (arrows). (B) Trp53 RT-PCR showing progressive and variable Trp53 loss of mouse lung adenocarcinomas. (C) Immunoblots of cytoplasmic tumor cell line extracts for protein products of key driver oncogenes and tumor suppressors. Shown are mouse lung adenocarcinomas and LLC (Kras mutant) lung adenocarcinoma, as well as CT26 (Kras mutant) and MC38 (Kras and Trp53 mutant) colon adenocarcinomas for comparison.

679345-SI.ACC

a Economic and/or recietal benefit

Lung cancer is the leading cancer killer worldwide causing 1.6 million deaths in 2012 (of which ~270 thousand in the EU-28 and 170 thousand in the US)** with hing adenocarcinoms accounting for half of the cases. This lung cancer epidemic poses a tremendous burden to States and Health Care systems The discovery of hing cancer-specific genetic alterations and biologic pathway signalling has led to the development and usage such as the promising category of EGFR inhibitors. These agents

0 1 2 2 7 10 12 20 31 ______ -- -- -- -- 193|545 | 273

inhibitor. Those agent
however, display residential activity against vary specific tumor type. Thus, in order to set a rational
framework for individualised cancer therapy, there is a pressing used for informative high throughput
modules of the distributions. Our nearly developed MLC promail inclose long certiciness cells feating affect
minitions in key drive canogeness and tumor suppressors researchely assimilating those of human lin
coll lines, runs has form and Type 57. We would like to make these, as well as custom made MLC cell. call lines, which is Now and Type?". We would his to make these, it well as custim made MLC, call bready writished by smallest be to used as a placine on finuses models and host genetic because the transitional ling cancer research worldwide will beautiff from a versarial experimental tool currently reacting. This syntamatic approach will be early bring us not supplemental tool currently reacting. This syntamatic approach will be early bring us not supplemental tool currently as the contract of the state of

b. Commercialization process and/or any other exploitation process

After a preliminary market evaluation of the potential commercialization options, two possibilities are

- The technology exploination through a start-up company. The funding costs will be derived five autional charrity funds and organizations willing to subsidize this venture (og Canasis Foundat Charrity Fund 'Starton Starton's Triands or Group EFFIDA-Association of Friends or Charles and Charles (Triands or Triands). Control with Cancer, all will be appropriately contricted, potential colemnific partners and/or founders.

 Alternatively we will seption the relatively recent flexible Greek legislation that permit the artibilities are in zero copies of a new copporate from (the Private Company Lid. PCL. or the se-called Che E Companies) by one or more natural or legal entity founders for which no reserved capital find
- licensing to an already existing company bearing the infrastructure to carry out the proposed to

Expected impact (2p)

Economic and/or societal benefits

Commercialisation process and/or any other exploitation process

Proposed plans for:

-Competitive analysis

-- Testing, technical reports

-- IPR position and strategy

-- Industry/sector contacts

Stathopoulos 679345-SLACC
The commercialization process carried out within WF3 will stable us to define the appropriate target group and to evaluate the market for the technology presented herein, to define a unitable commercialization strategy and to design the preliminary approaches to potential partners, investors and founders in society and pharmaceutical

- Competitive analysis A desirable analysis and be conducted. This rate aims to market evaluation study, to identify potential insusters and to understand the surgest market properties and characteristics, thus speeding up the sectnology commercialization. It will also help to identify long-term potential market niches. This analysis will be

- Testing, technical reports

Pipelined tests to ensure that all MLCs (existing and newly generated) comprise bona fide cancer cell lines as repeated nets to entire that the Conference and the order to globally assess guns expression and mutation status. For this, qualified team members have already set up collaborations with CRG (Barcelons, Spain) and the institute of Genetics at Oxford University (UR), defined panie of MLC cell lines will be constructed that will include cells with or without Kras, Kgfr, Trp53, and defining pass of MLC cell limits will be contributed that vall intrinde cells with or written from \$400. The MLC cell limits will be contributed that vall intrinde cells with or written from \$400. The MLC cell limits will be used to define until a season for differential season by the collection of the many cells of the season for the collection of the season from the cells of the c

 IPR position and strategy
 Under this PoC project WP2; a Freedom-to-operate search (FTO) will be performed and a detailed IPR study
 It is not an advance conflict or infringement risk concerning the intellectual property right. The product patent will be developed on the basis of the project results, scalability, scientific and technical impact. The patent prosecution including the priority patent application and international patent protection under the Patent Cooperation Treaty PCT, see Plan of the activities) will be carried out by collaborating or subcontracting a Technology Transfer Agent (or exploit the

- Industryl-sector consister.
 After a prolimatory market assessment, farse relevant staksholders have been identified for the process of commencialization.
 Commencialization.
 The commencialization of the commencialization of the commencialization.
 The commencial licenses. The European Association for Commer Research European Sociatry for medical cancelogy, Omassis Foundation, Charity Fand "Serves Nickriss", Lattia "A" Investor George, ELFIDA-Association of Friends of Collinea with Cinner.
 Technology transfer agencies. Such as Knowledge Innovation Market or MUC-International which will be the newpoints for performing a commencial prospecting with inclusivy and investor.

Section 3: The proof of concept plan (max 2 pages)

legenchin patentic patentic patent and entered in a divided into three work packages. A technical WPI is set up to cover the rele technical tests. All MLC cell lines (existing and newly generated) will be tested in vitro and in vivo in order to: i) security seef. All DAL. Cold indice (persisting an interpolary generating) with the instead on view has not write the context of the interpolary and interpolary and the interpolary and inter

This IPR strategy will sindy whether there are pending potent risks to compute or infinings the IPR of others. Thus a Freedom-to-operate analysis will be performed (M.C.). This IW will be completed with the relationation and management of patenting the product developed in this project (M.C.). The IF and the team will to a knowledgeable transfer again in order to carry out WP2 and WP3 activities. The last WP3 was deal with marketing and technology transfer matters. A market analysis and commercialization stra carried out (ML6 and ML7). Finally, with the support of the international network of the Technolo Agent potential partners or companies interested in the product will be approached (MLS).

b. Project-management plan
The management of the project will be performed by the Project Coordinator, the Administrator a
Technical Management —These agent will constitute the Steating Committee and set as the primary ducmation of the project. To grammine the cornect development of the Intellectual Property and Technical
sectition, an external Technically Terminer Agent will be unbountered.

The Project Coordinator will be the Principal Investigator, Dr. Georgios Stathopoulos. He has the The Project Coordinate will be the Principal Involgator, Dr. Gourgios Stringscools. He has the responsibility of chaning the Steaming Committee, and think the decision with the action of the school and the administrator. His main role in the project is the supervision of the steam, supervision of both Technical Manager will have the acceptability of the project securities of WPL, pucking and forms. Risk Assument. The searching of WPL and WPP will be subcommented to an extrant expert agent is chanloogly trainfer and communicationing pressor. The searching alter will report discretely to the Co. The percolaption of an extrant Experted Principal Committee will cause an expert importal extrant although the Co. The search of the Co. The percolaption of an extrant Experted Principal Co. The percolaption of an extrant Experted Principal Co. The percolaption of the section of the control of the Co. The percolaption of the section of the Co. The percolaption of the Co. The percolaption of the Section of the Co. The percolaption of the Co. The principal investigator while acquiring an expert advice on valorisation and commercialisation aspect

c. Description of the team

Georgies T. Stathopoules, MD PhD: Associate Professor of Physiology at Host Institution and Prin Investigator, Laboratory for Molecular Respiratory Carcinogenesis; former Assistant Professor of Re

Studiopoulos Studiopoulos (National Canter, Nashralla, TX, USA, ND (UParras, 1995); Palmonary Specialist training (University of Adama, 2001); PaD in more magiogenesis (University of Adama, 2007). 49 seasors politication citad 976 tames in 10 years, including first under popura in 1 Natl Canter Inter, Proc Natl Acad Sci USA, Am J Regio COI Can Medi Canter Research de und seasor tempera in Canter Inter, Proc Natl Acad Sci USA, Am J Regio COI Can Medi Canter Research de under papera in Canter Research Carteriogenesis, Neuglass, J Clin Interest, etc. Expert in lang cancer biology, name-both stancations in therefor inalignations and motion models of Canter. Will implement the project, supervise tochnical beneaty hypotring. Balls with light and technology insuffer sums, and chair televing committees. Sultry support for 10% months of the Canter University of the Ca

One senior Post-Doctoral Scientist: Will maintain and characterise MLC cell lines, supervise MLC line distribution, implement GLP tendered, perform STR and perforge noting, and avaist Fl in CLC commercialisation and collaborations (WP1). Will dedicate 90 % of research effort at senior post-doc salary scale = 20% at 8 2,000 ~ 2,000 monthly x 12 monthle = 2,8,000.

One junior Post-Dectoral Scientist: Will generate additional call lines, carry out similar testing in vitro and in vivo, backgrounds including genotyping, and perform lung carrinogenesis represents (WPI). Will dedicate 100% research effort at junior post-doc salary scale = 100% at 2.000 = 6.200 monthly a 12 months = 6.0400.

One PhD student in bioinformatics: Will perform and analyze RNA sequencing (WP1), Will dedicate 100% research effort at PhD Studenthip Scholarship salary scale = 100% x 6 33 = 6 33 monthly x 12 months = 6 10,000.

One part-time administrator: Will maintain project logistics, handle payments and invoices and assist PI. Will dedicate 15% effort at relevant salary scale = $15\% \times 92,000 = 9300$ monthly x 12 months = 93,600 for project

Technology Transfer Agent: This agent will be subcontracted, it will hold an important role in the project as specialist in transfer-of-knowledge and commercialization. The former company is an expert in medicing and commercialization, the latter is an expert in technology transfer and intellectual property, and it will help defining the IP strategy and understand the trapet medicits.

Section 4: The budget justification

Personnel: The total budget for the personnel cost is \in 76,000, as outlined in the team description. This budget will estall the rearmeration of the FI, the technical manager, the administrator and the scientists involved. This budget is necessary to perform the technical testing described under WF1.

Travel: A budget of €3,000 has been allocated for travelling. These costs will cover trips for networking with potential investors and partners inside and outside Greece.

Equipment: The equipment necessary has already been purchased for execution of the mother project.

Other Goods and Services: Estimated £ 10,850 will be spear for RNA sequencing. Other consumables dedicated to characterizing, culturing, and preserving estiting MLC lines, as well as potentially to generating new cost, including cell culture consumables and media £ 2,000, mouse maintannea costs £ 2,000). Sanger sequencing, PCR, mycoplasma testing kits etc (£ 1,850), will be covered by the mother project

Publications: € 1,300 will be allocated for publication and minor commercialization costs.

Subcontracting costs: € 35,650 are foreseen to cover the development of WP2 and WP3. The team has decided suscentrating of the seed to subcontract a Technology Transfer Agent. It will provide specific expertise in P management, commercialization strategies and regulatory issues, as well as an important external and objective

The PoC plan (2p)


Plan of the activities

Project-management plan

Description of the team

The budget justification

ERC Inform 14.01.2016 Information Day,





A Marazioti M Spella T Agalioti

I Lilis

I Giopanou

NI Kanellakis

N Spyropoulou

M Papageorgopoulou G Ntalliarda

G Giotopoulou

A Krontira

V Armenis

D Kati



